
Global Anti-Respiratory Syncytial Virus Drugs Market Growth 2023-2029
Description
Global Anti-Respiratory Syncytial Virus Drugs Market Growth 2023-2029
The global Anti-Respiratory Syncytial Virus Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Anti-Respiratory Syncytial Virus Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Anti-Respiratory Syncytial Virus Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Anti-Respiratory Syncytial Virus Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Anti-Respiratory Syncytial Virus Drugs players cover AstraZeneca, Sanofi, Janssen Pharmaceutica, Merck, Enanta Pharma, Pfizer, GSK, Shanghai Ark Biopharmaceutical and Walvax Biotechnology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Anti-Respiratory Syncytial Virus Drugs Industry Forecast” looks at past sales and reviews total world Anti-Respiratory Syncytial Virus Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Respiratory Syncytial Virus Drugs sales for 2023 through 2029. With Anti-Respiratory Syncytial Virus Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Respiratory Syncytial Virus Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-Respiratory Syncytial Virus Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Respiratory Syncytial Virus Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-Respiratory Syncytial Virus Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Respiratory Syncytial Virus Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Respiratory Syncytial Virus Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Respiratory Syncytial Virus Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Child Drug
Aldult Drug
Segmentation by application
Hospitals
Drugstores
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Sanofi
Janssen Pharmaceutica
Merck
Enanta Pharma
Pfizer
GSK
Shanghai Ark Biopharmaceutical
Walvax Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Anti-Respiratory Syncytial Virus Drugs market?
What factors are driving Anti-Respiratory Syncytial Virus Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Respiratory Syncytial Virus Drugs market opportunities vary by end market size?
How does Anti-Respiratory Syncytial Virus Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
94 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Anti-Respiratory Syncytial Virus Drugs Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Anti-Respiratory Syncytial Virus Drugs by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Anti-Respiratory Syncytial Virus Drugs by Country/Region, 2018, 2022 & 2029
- 2.2 Anti-Respiratory Syncytial Virus Drugs Segment by Type
- 2.2.1 Child Drug
- 2.2.2 Aldult Drug
- 2.3 Anti-Respiratory Syncytial Virus Drugs Sales by Type
- 2.3.1 Global Anti-Respiratory Syncytial Virus Drugs Sales Market Share by Type (2018-2023)
- 2.3.2 Global Anti-Respiratory Syncytial Virus Drugs Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Anti-Respiratory Syncytial Virus Drugs Sale Price by Type (2018-2023)
- 2.4 Anti-Respiratory Syncytial Virus Drugs Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Drugstores
- 2.4.3 Others
- 2.5 Anti-Respiratory Syncytial Virus Drugs Sales by Application
- 2.5.1 Global Anti-Respiratory Syncytial Virus Drugs Sale Market Share by Application (2018-2023)
- 2.5.2 Global Anti-Respiratory Syncytial Virus Drugs Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Anti-Respiratory Syncytial Virus Drugs Sale Price by Application (2018-2023)
- 3 Global Anti-Respiratory Syncytial Virus Drugs by Company
- 3.1 Global Anti-Respiratory Syncytial Virus Drugs Breakdown Data by Company
- 3.1.1 Global Anti-Respiratory Syncytial Virus Drugs Annual Sales by Company (2018-2023)
- 3.1.2 Global Anti-Respiratory Syncytial Virus Drugs Sales Market Share by Company (2018-2023)
- 3.2 Global Anti-Respiratory Syncytial Virus Drugs Annual Revenue by Company (2018-2023)
- 3.2.1 Global Anti-Respiratory Syncytial Virus Drugs Revenue by Company (2018-2023)
- 3.2.2 Global Anti-Respiratory Syncytial Virus Drugs Revenue Market Share by Company (2018-2023)
- 3.3 Global Anti-Respiratory Syncytial Virus Drugs Sale Price by Company
- 3.4 Key Manufacturers Anti-Respiratory Syncytial Virus Drugs Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Anti-Respiratory Syncytial Virus Drugs Product Location Distribution
- 3.4.2 Players Anti-Respiratory Syncytial Virus Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
- 4 World Historic Review for Anti-Respiratory Syncytial Virus Drugs by Geographic Region
- 4.1 World Historic Anti-Respiratory Syncytial Virus Drugs Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Anti-Respiratory Syncytial Virus Drugs Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Anti-Respiratory Syncytial Virus Drugs Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Anti-Respiratory Syncytial Virus Drugs Market Size by Country/Region (2018-2023)
- 4.2.1 Global Anti-Respiratory Syncytial Virus Drugs Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Anti-Respiratory Syncytial Virus Drugs Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Anti-Respiratory Syncytial Virus Drugs Sales Growth
- 4.4 APAC Anti-Respiratory Syncytial Virus Drugs Sales Growth
- 4.5 Europe Anti-Respiratory Syncytial Virus Drugs Sales Growth
- 4.6 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs Sales Growth
- 5 Americas
- 5.1 Americas Anti-Respiratory Syncytial Virus Drugs Sales by Country
- 5.1.1 Americas Anti-Respiratory Syncytial Virus Drugs Sales by Country (2018-2023)
- 5.1.2 Americas Anti-Respiratory Syncytial Virus Drugs Revenue by Country (2018-2023)
- 5.2 Americas Anti-Respiratory Syncytial Virus Drugs Sales by Type
- 5.3 Americas Anti-Respiratory Syncytial Virus Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Anti-Respiratory Syncytial Virus Drugs Sales by Region
- 6.1.1 APAC Anti-Respiratory Syncytial Virus Drugs Sales by Region (2018-2023)
- 6.1.2 APAC Anti-Respiratory Syncytial Virus Drugs Revenue by Region (2018-2023)
- 6.2 APAC Anti-Respiratory Syncytial Virus Drugs Sales by Type
- 6.3 APAC Anti-Respiratory Syncytial Virus Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe Anti-Respiratory Syncytial Virus Drugs by Country
- 7.1.1 Europe Anti-Respiratory Syncytial Virus Drugs Sales by Country (2018-2023)
- 7.1.2 Europe Anti-Respiratory Syncytial Virus Drugs Revenue by Country (2018-2023)
- 7.2 Europe Anti-Respiratory Syncytial Virus Drugs Sales by Type
- 7.3 Europe Anti-Respiratory Syncytial Virus Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs by Country
- 8.1.1 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs Sales by Type
- 8.3 Middle East & Africa Anti-Respiratory Syncytial Virus Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Anti-Respiratory Syncytial Virus Drugs
- 10.3 Manufacturing Process Analysis of Anti-Respiratory Syncytial Virus Drugs
- 10.4 Industry Chain Structure of Anti-Respiratory Syncytial Virus Drugs
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Anti-Respiratory Syncytial Virus Drugs Distributors
- 11.3 Anti-Respiratory Syncytial Virus Drugs Customer
- 12 World Forecast Review for Anti-Respiratory Syncytial Virus Drugs by Geographic Region
- 12.1 Global Anti-Respiratory Syncytial Virus Drugs Market Size Forecast by Region
- 12.1.1 Global Anti-Respiratory Syncytial Virus Drugs Forecast by Region (2024-2029)
- 12.1.2 Global Anti-Respiratory Syncytial Virus Drugs Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Anti-Respiratory Syncytial Virus Drugs Forecast by Type
- 12.7 Global Anti-Respiratory Syncytial Virus Drugs Forecast by Application
- 13 Key Players Analysis
- 13.1 AstraZeneca
- 13.1.1 AstraZeneca Company Information
- 13.1.2 AstraZeneca Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.1.3 AstraZeneca Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 AstraZeneca Main Business Overview
- 13.1.5 AstraZeneca Latest Developments
- 13.2 Sanofi
- 13.2.1 Sanofi Company Information
- 13.2.2 Sanofi Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.2.3 Sanofi Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Sanofi Main Business Overview
- 13.2.5 Sanofi Latest Developments
- 13.3 Janssen Pharmaceutica
- 13.3.1 Janssen Pharmaceutica Company Information
- 13.3.2 Janssen Pharmaceutica Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.3.3 Janssen Pharmaceutica Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Janssen Pharmaceutica Main Business Overview
- 13.3.5 Janssen Pharmaceutica Latest Developments
- 13.4 Merck
- 13.4.1 Merck Company Information
- 13.4.2 Merck Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.4.3 Merck Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Merck Main Business Overview
- 13.4.5 Merck Latest Developments
- 13.5 Enanta Pharma
- 13.5.1 Enanta Pharma Company Information
- 13.5.2 Enanta Pharma Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.5.3 Enanta Pharma Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 Enanta Pharma Main Business Overview
- 13.5.5 Enanta Pharma Latest Developments
- 13.6 Pfizer
- 13.6.1 Pfizer Company Information
- 13.6.2 Pfizer Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.6.3 Pfizer Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 Pfizer Main Business Overview
- 13.6.5 Pfizer Latest Developments
- 13.7 GSK
- 13.7.1 GSK Company Information
- 13.7.2 GSK Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.7.3 GSK Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.7.4 GSK Main Business Overview
- 13.7.5 GSK Latest Developments
- 13.8 Shanghai Ark Biopharmaceutical
- 13.8.1 Shanghai Ark Biopharmaceutical Company Information
- 13.8.2 Shanghai Ark Biopharmaceutical Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.8.3 Shanghai Ark Biopharmaceutical Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.8.4 Shanghai Ark Biopharmaceutical Main Business Overview
- 13.8.5 Shanghai Ark Biopharmaceutical Latest Developments
- 13.9 Walvax Biotechnology
- 13.9.1 Walvax Biotechnology Company Information
- 13.9.2 Walvax Biotechnology Anti-Respiratory Syncytial Virus Drugs Product Portfolios and Specifications
- 13.9.3 Walvax Biotechnology Anti-Respiratory Syncytial Virus Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.9.4 Walvax Biotechnology Main Business Overview
- 13.9.5 Walvax Biotechnology Latest Developments
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.